The scientist who developed the world's first highly effective malaria vaccine has been named winner of the European Inventor Award 2026 — one of the most prestigious science prizes in Europe. Sir Adrian Hill, an Irish-British professor at the University of Oxford's Jenner Institute, received the honor from the European Patent Office (EPO) in the Research category for his landmark R21/Matrix-M vaccine.

The R21/Matrix-M vaccine achieves around 75–80% protection against malaria in clinical trials — exceeding the World Health Organization's own target efficacy threshold for malaria vaccines, a bar that had been considered aspirational for decades. It is priced at under €3 per dose, making it accessible to the high-burden regions of sub-Saharan Africa where malaria remains one of the leading killers of children under five.

'This vaccine represents a genuine turning point in the fight against one of humanity's oldest diseases,' the EPO noted in its announcement. Its efficacy, stability under real-world conditions, and affordability together create a pathway to protection that simply did not exist before.

Malaria kills hundreds of thousands of people each year — the vast majority of them young children in Africa. Despite more than a century of scientific effort, an effective vaccine had proven extraordinarily elusive. The parasite that causes the disease, Plasmodium falciparum, is transmitted through the bites of Anopheles mosquitoes and has evolved sophisticated mechanisms to evade the human immune system, making vaccine design exceptionally difficult.

Hill's team at Oxford, working in collaboration with the Serum Institute of India, Novavax, and a network of global health partners, took a novel approach: pairing a carefully selected antigen targeting the parasite at its sporozoite stage with Matrix-M, a powerful adjuvant developed by Novavax that dramatically amplifies the immune response. The combination proved decisive.

The WHO formally recommended R21/Matrix-M for widespread use, and the vaccine has since been adopted into childhood immunization programs across multiple African countries. A key advantage has been its stability under real-world conditions, particularly in health systems without reliable cold-chain infrastructure — a practical consideration that has been critical to its impact in the field.

Beyond R21, Hill's laboratory has had an outsized effect on global health. His team also contributed critical elements to the Oxford-AstraZeneca COVID-19 vaccine, which was manufactured and distributed at scale during the pandemic. Together, these two vaccines are estimated to have helped save more than six million lives between 2021 and 2025.

The European Inventor Award is presented annually by the EPO to recognize inventors from Europe and around the world whose work has made outstanding contributions to innovation, the economy, society, and technological progress. Hill is the first inventor to be recognized for malaria vaccine development in the award's history.

For Hill, the recognition is secondary to the work still ahead. In recent statements, he has emphasized that malaria vaccination still isn't reaching everyone who needs it — and that the same vaccine platforms could be adapted to tackle other neglected tropical diseases that have long lacked effective prevention tools.

The battle against malaria is not yet over. But with a vaccine that actually works at scale, the end has come into view.